ReviewStroke research and treatment2026
Ticagrelor Versus Clopidogrel or Aspirin in Secondary Stroke Prevention: Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Review in Stroke research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ticagrelor Versus Clopidogrel or Aspirin in Secondary Stroke Prevention: Systematic Review and Meta-Analysis of Randomized Controlled Trials.Stroke research and treatment · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ticagrelor, a direct-acting P2Y Methods: A systematic search of PubMed, Embase, CENTRAL, and Chinese databases was conducted to identify randomized controlled trials comparing ticagrelor with aspirin or clopidogrel in this population. The primary outcomes were recurrent stroke and major bleeding. Random-effects meta-analyses were performed, and heterogeneity was assessed using the Results: Six randomized controlled trials were included. Ticagrelor significantly reduced the risk of recurrent stroke compared to control (pooled OR: 0.78; 95% CI: 0.70-0.89; Conclusion: Ticagrelor offers superior efficacy over clopidogrel or aspirin in preventing recurrent stroke, with no excess risk of major bleeding. It may be particularly beneficial in patients with poor clopidogrel metabolism or high recurrence risk. Further research is needed to establish its long-term safety, cost-effectiveness, and optimal use in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.